Med Ed 101
AUGUST 27, 2023
I know some folks out there really like crossword puzzles, so I figured why not combine a little fun with a little pharmacology education? I’ve created a free brand/generic crossword puzzle that you should be able to work through below. The main focus of this crossword puzzle is old school medications. The answers to the […] The post Old School Brand/Generic Crossword Puzzle appeared first on Med Ed 101.
Pharmaceutical Technology
AUGUST 27, 2023
Selinexor is under clinical development by Karyopharm Therapeutics and currently in Phase II for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The FDA Law Blog
AUGUST 27, 2023
By Karla L. Palmer — On Friday, August 25, 2023, FDA released a much-anticipated Final Guidance titled, “Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act,” addressing FDA’s implementation of certain electronic interoperability provisions of the Drug Supply Chain Security Act (DSCSA), which were due to become effective on November 27, 2023.
Pharmaceutical Technology
AUGUST 27, 2023
Patidistrogene bexoparvovec is a gene therapy commercialized by Sarepta Therapeutics, with a leading Phase II program in Limb-Girdle Muscular Dystrophy.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Store News
AUGUST 27, 2023
The one-year delay allows for smoother implementation and a better patient experience, NCPA said.
Pharmaceutical Technology
AUGUST 27, 2023
Selinexor is under clinical development by Karyopharm Therapeutics and currently in Phase II for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis).
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmaceutical Technology
AUGUST 27, 2023
Following public outcry and a government investigation, Allina Health has reneged on their policy barring debtors from out-patient care.
Drug Store News
AUGUST 27, 2023
Himalaya Wellness is introducing blackberry-flavored, vegan Ashwagandha Organic Gummies.
Pharmaceutical Technology
AUGUST 27, 2023
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Cardiovascular Disease.
Drug Store News
AUGUST 27, 2023
Himalaya Wellness is introducing blackberry-flavored, vegan Ashwagandha Organic Gummies.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmaceutical Technology
AUGUST 27, 2023
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Cardiovascular Disease.
Drug Store News
AUGUST 27, 2023
Apricot, Rose and Unfragranced are the three new exfoliating toners offered by St. Ives.
Pharmaceutical Technology
AUGUST 27, 2023
Safinamide mesylate is under clinical development by Zambon Co and currently in Phase II for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration).
Pharmaceutical Technology
AUGUST 27, 2023
Safinamide mesylate is under clinical development by Zambon Co and currently in Phase II for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration).
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmaceutical Technology
AUGUST 27, 2023
Zanidatamab is a monoclonal antibody commercialized by Jazz Pharmaceuticals, with a leading Phase III program in Adenocarcinoma Of The Gastroesophageal Junction.
Pharmaceutical Technology
AUGUST 27, 2023
Quisovalimab is a monoclonal antibody commercialized by Avalo Therapeutics, with a leading Phase II program in Crohn's Disease (Regional Enteritis).
Pharmaceutical Technology
AUGUST 27, 2023
Lutetium (lu177) lilotomab satetraxetan is under clinical development by Thor Medical and currently in Phase II for B-Cell Chronic Lymphocytic Leukemia.
Pharmaceutical Technology
AUGUST 27, 2023
Lutetium (lu177) lilotomab satetraxetan is under clinical development by Thor Medical and currently in Phase II for B-Cell Chronic Lymphocytic Leukemia.
Pharmaceutical Technology
AUGUST 27, 2023
Linavonkibart is a monoclonal antibody commercialized by Scholar Rock Holding, with a leading Phase I program in Non-Small Cell Lung Cancer.
Pharmaceutical Technology
AUGUST 27, 2023
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Duodenal Ulcer.
Pharmaceutical Technology
AUGUST 27, 2023
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Gastric Ulcers.
Pharmaceutical Technology
AUGUST 27, 2023
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Duodenal Ulcer.
Pharmaceutical Technology
AUGUST 27, 2023
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Gastric Ulcers.
Expert insights. Personalized for you.
97 
Let's personalize your content